CoChat

Semaglutide in Patients With Obesity and Heart Failure Across Mildly Reduced or Preserved Ejection Fraction

Open access
Butler, Javed, Abildstrøm, Steen Z., Borlaug, Barry A., Davies, Melanie J., Kitzman, Dalane W., Petrie, Mark C., Shah, Sanjiv J., Verma, Subodh, Abhayaratna, Walter P., Chopra, Vijay, Ezekowitz, Justin A., Fu, Michael, Ito, Hiroshi, Lelonek, Małgorzata, Núñez, Julio, Perna, Eduardo, Schou, Morten, Senni, Michele, van der Meer, Peter, von Lewinski, Dirk, Wolf, Dennis, Altschul, Rebecca L., Rasmussen, Søren, Kosiborod, Mikhail N. · 2023 · Journal of the American College of Cardiology
Cited by 88

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Many therapies for heart failure (HF) have shown differential impact across the spectrum of left ventricular ejection fraction (LVEF). OBJECTIVES: In this prespecified analysis, the authors assessed the effects of semaglutide across the baseline LVEF strata in patients with the obesity phenotype of HF with preserved ejection fraction (HFpEF) in the STEP-HFpEF (Semaglutide Treatment Effect in People with obesity and HFpEF) trial. METHODS: STEP-HFpEF randomized 529 patients (263 semaglutide; 266 placebo). For this prespecified analysis, patients were categorized into 3 groups based on LVEF: 45% to 49% (n = 85), 50% to 59% (n = 215), and ≥60% (n = 229). RESULTS: At 52 weeks, semaglutide improved the dual primary endpoints of Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (estimated treatment difference: EF [ejection fraction] 45%-49%: 5.0 points [95% CI: -2.7 to 12.8 points], EF 50%-59%: 9.8 points [95% CI: 5.0 to 14.6 points], and EF ≥60%: 7.4 points [95% CI: 2.8 to 12.0 points]; P interaction = 0.56) and body weight (EF: 45%-49%: -7.6 [95% CI: -10.7 to -4.4], EF 50%-59%: -10.6 [95% CI: -12.6 to -8.6] and EF ≥60%: -11.9 [95% CI: -13.8 to -9.9]; P interaction = 0.08), to a similar extent across LVEF categories. Likewise, LVEF did not influence the benefit of semaglutide on confirmatory secondary endpoints: 6-minute walk distance (P interaction = 0.19), hierarchal composite endpoint (P interaction = 0.43), and high-sensitivity C-reactive protein (P interaction = 0.26); or exploratory endpoint of N-terminal pro-brain natriuretic peptide (P interaction = 0.96). Semaglutide was well-tolerated across LVEF categories. CONCLUSIONS: In patients with HFpEF and obesity, semaglutide 2.4 mg improved symptoms, physical limitations, and exercise function, and reduced inflammation and body weight to a similar extent across LVEF categories. These data support treatment with semaglutide in patients with the obesity phenotype of HFpEF regardless of LVEF. (Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity [STEP-HFpEF]; NCT04788511).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jacc.2023.09.811

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 12

  1. Wagner, 1977, Heart failure. A proposed definition and classification, Arch Intern Med, 137, 675, 10.1001/archinte.1977.03630170075017 · DOI
  2. Heidenreich, 2022, 2022 AHA/ACC/HFSA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines, J Am Coll Cardiol, 79, 1757, 10.1016/j.jacc.2021.12.011 · DOI · Paper page
  3. Bozkurt, 2021, J Card Fail, 27, P387, 10.1016/j.cardfail.2021.01.022 · DOI · Paper page
  4. Solomon, 2016, Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction, Eur Heart J, 37, 455, 10.1093/eurheartj/ehv464 · DOI · Paper page
  5. Lund, 2018, Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum, Eur J Heart Fail, 20, 1230, 10.1002/ejhf.1149 · DOI · Paper page
  6. Paulus, 2022, Border disputes between heart failure phenotypes, Circulation, 145, 1374, 10.1161/CIRCULATIONAHA.121.058516 · DOI
  7. Rosch, 2022, Characteristics of heart failure with preserved ejection fraction across the range of left ventricular ejection fraction, Circulation, 146, 506, 10.1161/CIRCULATIONAHA.122.059280 · DOI
  8. Packer, 2023, A reclassification of heart failure based on recognition of heart failure with normal to supernormal ejection fraction, a clinically common form of cardiac contracture, with distinctive pathophysiological and therapeutic features, Eur J Heart Fail, 25, 669, 10.1002/ejhf.2849 · DOI
  9. Popovic, 2023, Ventricular stiffening and chamber contracture in heart failure with higher ejection fraction, Eur J Heart Fail, 25, 657, 10.1002/ejhf.2843 · DOI
  10. Bhatt, 2023, Effect of dapagliflozin on health status and quality of life across the spectrum of ejection fraction: participant-level pooled analysis from the DAPA-HF and DELIVER trials, Eur J Heart Fail, 25, 981, 10.1002/ejhf.2909 · DOI
  11. Nassif, 2023, Dapagliflozin improves heart failure symptoms and physical limitations across the full range of ejection fraction: pooled patient-level analysis from DEFINE-HF and PRESERVED-HF trials, Circ Heart Fail, 16, 10.1161/CIRCHEARTFAILURE.122.009837 · DOI
  12. Verma, 2023, A big STEP for treatment of heart failure with preserved ejection fraction, Cell Metab, 35, 1681, 10.1016/j.cmet.2023.08.003 · DOI

Cited by

See all 88

Metadata

Authors
Butler, J., Abildstrøm, S. Z., Borlaug, B. A., Davies, M. J., Kitzman, D. W., Petrie, M. C., Shah, S. J., Verma, S., Abhayaratna, W. P., Chopra, V., Ezekowitz, J. A., Fu, M., Ito, H., Lelonek, M., Núñez, J., Perna, E., Schou, M., Senni, M., van der Meer, P., von Lewinski, D., Wolf, D., Altschul, R. L., Rasmussen, S., & Kosiborod, M. N.
Venue
Journal of the American College of Cardiology
Publisher
Elsevier BV
Published
2023-11
Volume
82
Issue
22
Pages
2087-2096
ISSN
0735-1097 (ISSN-L)
OpenAlex
W4387455980
Cited by
88
References
14
FWCI
15.48
Type
journal article
Language
en
Open access
hybrid
Licence
Funders
Novo Nordisk

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.